Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Marshall Teitelbaum who wrote (1696)	11/13/1998 12:36:00 AM
From: Rick Strange	Respond to of 2205

Marshall, as you pointed out, starting in the forth quarter all domestic sales of TransCyte will be by the S&N sales force. Till now sales were under the control of ATIS with a very small sales staff. However; sales growth has been pretty impressive $1,238,000 for the quarter that includes $723,000 to the partnership at cost. I too look forward to the forth quarter growth now that the much larger S&N sales team is on the job.